Publications by authors named "Matthew D Biniakewitz"
Purpose: This phase Ib trial was designed to evaluate the safety and early efficacy signal of the combination of imatinib and binimetinib in patients with imatinib-resistant advanced gastrointestinal stromal tumors (GISTs).
Patients And Methods: This trial used a standard 3 + 3 design to determine the recommended phase II dose (RP2D). Additional patients were enrolled on an expansion cohort at the RP2D enriching for succinate dehydrogenase (SDH)-deficient GISTs to explore potential efficacy.
Article Synopsis
- A clinical trial investigated the combined effects of imatinib and binimetinib as a first-line treatment for advanced gastrointestinal stromal tumors (GISTs) to enhance efficacy compared to imatinib alone.
- The trial included treatment-naive adult patients, aiming for a 20% improvement in best objective response rate (ORR), with 29 out of 42 patients achieving confirmed partial responses, resulting in an ORR of 69%.
- Additional findings showed a median progression-free survival of 29.9 months, successful pathologic responses in patients undergoing surgery, and manageable toxicity levels without unexpected adverse effects.
Objective: Older adults with cancer (OAC) may be at elevated risk for immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI) therapy due to the normal organ function changes of aging, as well as related to a higher prevalence of comorbid conditions compared to younger patients. The importance of high-quality nursing care cannot be overstated for this population, including proactive symptom assessment, management, and coordination of care. The purpose of this paper is to describe the unique challenges faced by OAC receiving ICI drugs.
View Article and Find Full Text PDF